US STOCKS-Futures flat as earnings pour in; Fed decision looms
- Country:
- United States
U.S. stock index futures were little changed on Wednesday as investors digested a fresh batch of earnings reports ahead of a widely expected interest rate cut by the Federal Reserve later in the day.
The central bank has already lowered borrowing costs twice this year, with a drawn-out U.S.-China trade war taking a toll on the domestic economy and raising fears of a slowdown. Odds of a rate cut have ballooned to over 97% from about 40% a month earlier. Hopes of a rate cut and optimism around trade talks have pushed the benchmark S&P 500 to record highs in the last two sessions.
Nearly half of the S&P 500 companies have posted quarterly results so far, of which 77.1% have beaten profit estimates. Still, analysts are expecting a 1.9% drop in third-quarter earnings, according to Refinitiv data. General Electric Co gained 5.2% in premarket trading after the industrial conglomerate beat quarterly profit estimates and raised its cash forecast for the year.
Advanced Micro Devices Inc dropped 1.3% after the chipmaker forecast fourth-quarter sales below expectations. Before the Fed's policy decision, a Commerce Department's gross domestic product report is likely to indicate that the U.S. economy is losing speed, but not tipping into recession.
The data, due at 8:30 a.m. ET is likely to show the U.S. economy slowed to 1.6% in the third quarter from 2% in the April-June period. At 7:15 a.m. ET, Dow e-minis remained unchanged. S&P 500 e-minis were up 0.75 points, or 0.02% and Nasdaq 100 e-minis were up 7.75 points, or 0.1%.
Among other stocks, Mattel Inc surged nearly 20% after the toymaker reported a surprise jump in quarterly revenue on higher demand for newer models of its flagship Barbie brand and dolls based on Korean pop-sensation BTS. Johnson & Johnson rose 2.8% as the company said 15 new tests found no asbestos in a bottle of baby powder that the U.S. Food and Drug Administration says tested positive for trace amounts of asbestos. FDA said it stands by its finding.
Google News